Canoga Perkins Brings Breakthrough Private 5G Technology to the BLOQUE Innovation Hub in Queretaro, Mexico
28.1.2026 14:00:00 CET | Business Wire | Press Release
Canoga Perkins, a global leader in Private 5G network connectivity solutions, announces their first international Private 5G Customer Experience Center at the BLOQUE in Queretaro, Mexico. On January 16th, 2026 the company demonstrated the SyncMetra® 100 product and an end-to-end Private 5G solution at the “Experiencing SyncMetra®” event attended by government representatives, city representatives, industry leaders, technology partners, system integrators, resellers and end customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128847071/en/
Querétaro invests in becoming a global hub for advanced manufacturing, industrial automation, smart agriculture and tech advanced ports applications; the demand for reliable, high-speed connectivity has never been higher. SyncMetra® 100 and Canoga Perkins arrive as critical enablers of Deterministic Networking for all these applications. The SyncMetra Platform offers a software-defined, IT-operated 5G network transport solution that guarantees the ultra-low latency required for next-generation industrial applications.
Revolutionizing Connectivity in Mexico – Unlike traditional wireless solutions, SyncMetra is purpose-built to support Time Sensitive Networking (TSN). This capability allows enterprises to deploy various mission critical applications —such as robotic control, Enterprise AI, and AR/VR, manufacturing and automation—without the lag or instability inherent in standard cellular or Wi-Fi networks. As part of the event, Canoga Perkins demonstrated an industrial robotic arm operating flawlessly over an Ultra-Low Latency Private 5G Network supported by SyncMetra.
"Bringing SyncMetra to Mexico is a major milestone for Canoga Perkins and we are gratified by the overwhelming response from industry leaders here," said Malik Arshad, President of Canoga Perkins. "Deterministic networking removes the barriers to digital transformation for the most critical applications. The Bloque is a venue for furthering technology, innovation and digital entrepreneurship. It’s fitting that we are demonstrating that deterministic Private 5G and 5G TSN are no longer future concepts— we take pride in developing leading edge solutions that show that these technologies are ready for deployment today."
Key Technology Highlights:
- Determinism: Guaranteed Quality of Service (QoS) for real-time industrial communication.
- Ultra-Reliable Low-Latency (URLLC): Precise packet delivery essential for mission-critical automation.
- IT-Centric Operation: Cloud-managed orchestration via SyncMetra Manager™ (SMM) for ease of use.
- Scalable Architecture: Expands easily to cover large manufacturing floors or complex campus environments.
About the Bloque
BLOQUE is the Innovation and Technology Center of the Municipality of Querétaro, promoted by the Ministry of Innovation and Technology. It is a unique public space in Mexico, designed so that anyone – students, entrepreneurs, professionals, companies and organizations – can learn, create and connect through technology, innovation and talent training. In BLOQUE, citizens find the tools to build tomorrow. We are the space that invites you to create, not just observe. Here ideas come to life and dreams are transformed. We are more than a place: we are the community of the future.
Find out more: BLOQUE - ¿Qué es BLOQUE?
About Canoga Perkins
With over five decades of engineering excellence, Canoga Perkins has consistently led the charge in delivering mission-critical network solutions that empower industries to innovate and thrive. Trusted by leading service providers, industrial enterprises, utilities, military branches, and government agencies, Canoga Perkins combines a rich legacy with a relentless drive for innovation. We lead with AI whenever possible, designing intelligent solutions that are not only reliable and secure but also scalable and adaptable, ensuring our clients are always at the forefront of technological advancement.
Learn more at www.canogaperkins.net.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128847071/en/
Contacts
Marketing Contact
Amber Flores, Marketing
marketing@canogaperkins.net
+1-818-678-3856
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom